Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

114.27 -2.44 (-2.09%)

Streaming Delayed Price Updated: 10:21 AM EDT, Jul 13, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	144,572
Open	115.97
Bid (Size)	114.18 (100)
Ask (Size)	114.35 (100)
Prev. Close	116.71
Today's Range	113.80 - 116.02
52wk Range	67.17 - 118.97
Shares Outstanding	222,430,635
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

Today 4:00 EDT

From Incyte

Via Business Wire

Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks

July 12, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f...

Via StockStory

Performance

YTD	+12.7%	+12.7%
1 Month	+5.3%	+5.3%
3 Month	+19.6%	+19.6%
6 Month	+7.5%	+7.5%
1 Year	+63.3%	+63.3%

More News

2 Fast-Growing Pharmaceutical Stocks to Buy Now ↗

July 08, 2026

Via The Motley Fool

Incyte to Report Second Quarter Financial Results

July 08, 2026

From Incyte

Via Business Wire

Incyte Corp (NASDAQ:INCY) Screens as a Deep Value Opportunity with Strong Profitability ↗

June 05, 2026

Via Chartmill

Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio

July 06, 2026

From Incyte

Via Business Wire

1 Mid-Cap Stock to Research Further and 2 We Avoid

July 03, 2026

Via StockStory

Hormuz Goes Quiet, Software Wakes Up, and Burry Picks a Side ↗

June 29, 2026

Via Chartmill

1 Cash-Producing Stock with Solid Fundamentals and 2 We Turn Down

June 29, 2026

Via StockStory

2 Growth Stocks to Add to Your Roster and 1 We Avoid

June 22, 2026

Via StockStory

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

June 19, 2026

From Incyte Biosciences Japan G.K.

Via Business Wire

Top S&P500 movers in Monday's session ↗

June 15, 2026

Via Chartmill

Monday's session: top gainers and losers in the S&P500 index ↗

June 15, 2026

Via Chartmill

Which S&P500 stocks are gapping on Monday? ↗

June 15, 2026

Via Chartmill

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

June 14, 2026

From Mirum Pharmaceuticals, Inc. and Incyte

Via Business Wire

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia

June 13, 2026

From Incyte

Via Business Wire

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival

June 13, 2026

From Incyte

Via Business Wire

Top S&P500 movers in Wednesday's session ↗

June 10, 2026

Via Chartmill

Why Incyte (INCY) Stock Is Up Today

June 10, 2026

Via StockStory

2 S&P 500 Stocks for Long-Term Investors and 1 Facing Challenges

June 10, 2026

Via StockStory

Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles ↗

June 08, 2026

Via The Motley Fool

Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders

June 08, 2026

From Incyte

Via Business Wire

Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026

June 04, 2026

From Mirum Pharmaceuticals, Inc. and Incyte

Via Business Wire

Wednesday's session: top gainers and losers in the S&P500 index ↗

June 03, 2026

Via Chartmill

These S&P500 stocks are moving in today's session ↗

June 03, 2026

Via Chartmill

Frequently Asked Questions

Is Incyte Corporation - Common Stock publicly traded?

Yes, Incyte Corporation - Common Stock is publicly traded.

What exchange does Incyte Corporation - Common Stock trade on?

Incyte Corporation - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Incyte Corporation - Common Stock?

The ticker symbol for Incyte Corporation - Common Stock is INCY on the Nasdaq Stock Market

What is the current price of Incyte Corporation - Common Stock?

The current price of Incyte Corporation - Common Stock is 114.27

When was Incyte Corporation - Common Stock last traded?

The last trade of Incyte Corporation - Common Stock was at 07/13/26 10:21 AM ET

What is the market capitalization of Incyte Corporation - Common Stock?

The market capitalization of Incyte Corporation - Common Stock is 25.42B

How many shares of Incyte Corporation - Common Stock are outstanding?

Incyte Corporation - Common Stock has 25B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.